Perez_2010_Mol.Pharmacol_78_971

Reference

Title : alpha6ss2* and alpha4ss2* nicotinic receptors both regulate dopamine signaling with increased nigrostriatal damage: relevance to Parkinson's disease - Perez_2010_Mol.Pharmacol_78_971
Author(s) : Perez XA , Bordia T , McIntosh JM , Quik M
Ref : Molecular Pharmacology , 78 :971 , 2010
Abstract :

Nicotinic receptors (nAChRs) are important modulators of dopaminergic transmission in striatum, a region critical to Parkinson's disease. The nAChRs mainly involved are the alpha6beta2* and alpha4beta2* subtypes. Lesion studies show that the alpha6beta2* receptor is decreased to a much greater extent with nigrostriatal damage than the alpha4beta2* subtype raising the question whether this latter nAChR population is more important with increased nigrostriatal damage. To address this, we investigated the effect of varying nigrostriatal damage on alpha6beta2* and alpha4beta2* receptor-modulated dopamine signaling using cyclic voltammetry. This approach offers the advantage that changes in dopamine release can be observed under different neuronal firing conditions. Total single-pulse-evoked dopamine release decreased in direct proportion to declines in the dopamine transporter and dopamine uptake. We next used alpha-conotoxinMII and mecamylamine to understand the role of the alpha4beta2* and alpha6beta2* subtypes in release. Single-pulse-stimulated alpha6beta2* and alpha4beta2* receptor dopamine release decreased to a similar extent with increasing nigrostriatal damage, indicating that both subtypes contribute to the control of dopaminergic transmission with lesioning. Total burst-stimulated dopamine release also decreased proportionately with nigrostriatal damage. However, the role of the alpha4beta2* and alpha6beta2* nAChRs varied with different degrees of lesioning, suggesting that the two subtypes play a unique function with burst firing, with a somewhat more prominent and possibly more selective role for the alpha6beta2* subtype. These data have important therapeutic implications because they suggest that drugs directed to both alpha4beta2* and alpha6beta2* nAChRs may be useful in the treatment of neurological disorders such as Parkinson's disease.

PubMedSearch : Perez_2010_Mol.Pharmacol_78_971
PubMedID: 20732972

Related information

Citations formats

Perez XA, Bordia T, McIntosh JM, Quik M (2010)
alpha6ss2* and alpha4ss2* nicotinic receptors both regulate dopamine signaling with increased nigrostriatal damage: relevance to Parkinson's disease
Molecular Pharmacology 78 :971

Perez XA, Bordia T, McIntosh JM, Quik M (2010)
Molecular Pharmacology 78 :971